Clinical Observation of Jinhua Qinggan Granule in Treating Pneumonia Infected by Novel Coronavirus / 金花清感颗粒治疗新型冠状病毒感染肺炎的临床观察

ABSTRACT

Objective To observe the novel coronavirus Qinggan Granule in treating pneumonia caused by new coronavirus infection. Methods one hundred and twenty-three patients with covid-19 were randomly divided into treatment group (treated with Jinhua Qinggan Granules Combined with conventional treatment) and control group (treated with conventional treatment only), with 82 cases in the treatment group and 41 cases in the control group, The clinical symptom disappearance rate, TCM Syndrome Scale score, hospitalization rate, Hamilton Anxiety Scale score, outpatient satisfaction score and incidence of adverse reactions were observed before and after treatment for 5 days. Results there was no significant difference in baseline data between the two groups. The disappearance rates of clinical symptoms in treatment group and control group were as follows fever 80.3% and 53.1%, cachexia 80.8% and 81.3%, headache and body pain 77.8% and 66.7%, head and body weight 75.0% and 88.9%, fatigue 77.6% and 53.8%, cough 66.1% and 42.9%, expectoration 85.3% and 46.2%, sore throat 77.8% and 60.0%, pharyngitis 85.7% and 75.0%, dry throat 83.3% and 100.0%, nasal congestion and runny nose 87.5% and 66.7%, nausea and vomiting 83.3% and 71.4%. The hospitalization rate was 10.98% and 24.39% respectively, and the incidence of adverse reactions was 32.93% and 0. The disappearance rate of clinical fever, cough, fatigue, expectoration symptoms, TCM Syndrome Scale score and Hamilton Anxiety Scale score in the treatment group were significantly lower than those in the control group (P < 0.05 or P < 0.01), There was no significant difference in the hospitalization rate, the disappearance rate of chills, head and body pain, head and body weight, sore throat, itchy throat, dry throat, nasal congestion, runny nose, nausea and vomiting, and outpatient satisfaction score between the treatment group and the control group (P > 0.05), but the hospitalization rate was lower than that of the control group, The disappearance rate of head and body pain, sore throat, itchy throat, stuffy nose and runny nose, nausea and vomiting were higher than those in the control group. The disappearance rate of symptoms was higher in both groups. The novel coronavirus granule can significantly reduce the fever, cough, fatigue and expectoration of the new coronavirus pneumonia patients and relieve their psychological anxiety.

摘要

目的 观察金花清感颗粒治疗新型冠状病毒感染肺炎的临床疗效。方法 将123例COVID-19患者按照21随机分为治疗组(给予金花清感颗粒联合常规治疗)和对照组(仅给予常规治疗),其中治疗组82例,对照组41例,观察两组患者治疗前和治疗5天后的临床症状消失率、中医证候量表评分、住院率、汉密尔顿焦虑量表评分、门诊满意度评分及不良反应发生率。结果 两组患者基线资料比较差异无统计学意义。治疗组和对照组患者治疗后临床症状消失率发热80.3%和53.1%,恶寒80.8%和81.3%,头身痛77.8%和66.7%,头身重75.0%和88.9%,乏力77.6%和53.8%,咳嗽66.1%和42.9%,咳痰85.3%和46.2%,咽痛77.8%和60.0%,咽痒85.7%和75.0%,咽干83.3%和100.0%,鼻塞流涕87.5%和66.7%,恶心呕吐83.3%和71.4%。住院率分别为10.98%和24.39%,不良反应发生率分别为32.93%和0。治疗组临床发热、咳嗽、乏力、咳痰症状消失率、中医证候量表评分、汉密尔顿焦虑量表评分均较对照组明显降低(P<0.05或P<0.01),治疗组住院率以及恶寒、头身痛、头身重、咽痛、咽痒、咽干、鼻塞流涕、恶心呕吐等症状消失率及门诊满意度评分与对照组比较差异无统计学意义(P>0.05),但住院率较对照组有降低趋势,而头身痛、咽痛、咽痒、鼻塞流涕、恶心呕吐等症状消失率较对照组有升高趋势。两组患者症状消失率均较高。结论 金花清感颗粒能显著减轻新型冠状病毒肺炎轻型患者的发热、咳嗽、乏力、咳痰临床症状,缓解患者心理焦虑。